The role of botulinum therapy in the complex recovery of patients after stroke
https://doi.org/10.51793/OS.2025.28.1.009
Abstract
Background. The II All-Russian Neurocongress with international participation was held in Moscow on 10-12 October 2024. The main scientific directions of the Congress included the following topics: acute and chronic cerebral circulatory disorders, epilepsy and paroxysmal states, infectious diseases of the nervous system, cognitive disorders, hereditary degenerative diseases of the nervous system, traumas of the brain and spinal cord, rehabilitation in diseases of the nervous system, neurology of the elderly, new technologies in the diagnosis and treatment of stroke and many others.
Results. At the satellite symposium of Merz Pharma LLC ‘Organisation of rehabilitation of post-stroke patients with spasticity at the regional level’ held within the framework of the congress, the latest approaches to rehabilitation of stroke patients were discussed.
About the Author
M. V. Chirkova
The Lechaschy Vrach journal
Россия
Россия
Marina V. Chirkova - editor of The Lechaschy Vrach journal.
a/z 82 Moscow, 123056
References
1. Opheim A., Danielsson A., Murphy M. A., et al. Upper-limb spasticity during the first year after stroke: stroke arm longitudinal study at the University of Gothenburg. Am J Phys Med Rehabil. 2014; 93 (10): 884-896. DOI: 10.1097/PHM.0000000000000157.
2. Wissel J., Manack A., Brainin M. Toward an epidemiology of poststroke spasticity. Neurology. 2013; 80 (3 Suppl 2): S13-19. DOI: 10.1212/WNL.0b013e3182762448.
3. Lundström E., Smits A., Terént A., Borg J. Time-course and determinants of spasticity during the first six months following first-ever stroke. J Rehabil Med. 2010; 42: 296-301.
4. Li Sh., Francisco G. E., Rymer W. Z. A new defenition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages. Neurorehabil Neural Repair. 2021; 35 (7): 601-610. DOI: 10.1177/15459683211011214.
5. Marsden J., Stevenson V., Jarrett L. Treatment of spasticity. Handb Clin Neurol. 2023;196: 497-521. DOI: 10.1016/B978-0-323-98817-9.00010-7.
6. Triccas L. T., Kennedy N., Smith T., Pomeroy V. Predictors of upper limb spasticity after stroke? A systematic review and meta-analysis. Physiotherapy. 2019; 105 (2): 163-173. DOI: 10.1016/j.physio.2019.01004.
7. Gohritz A., Jan Fridén J. Management of Spinal Cord Injury-Induced Upper Extremity Spasticity. Hand Clin. 2018; 34 (4): 555-565. DOI: 10.1016/j.hcl.2018.07.001.
8. Halabchi F., Alizadeh Z., Sahraian M. A., Abolhasani M. Exercise prescription for patients with multiple sclerosis; potential benefits and practical recommendations. BMC Neurol. 2017; 17 (1): 185. DOI: 10.1186/s12883-017-0960-9.
9. Kong K. H., Lee J., Chua K. S. Occurrence and temporal evolution of upper limb spasticity in stroke patients admitted to a rehabilitation unit. Arch Phys Med Rehabil. 2012; 93 (1): 143-148. DOI: 10.1016/j.apmr.2011.06.027.
10. Instructions for use, 2024. (In Russ.)
11. Kaňovský P., Slawek J., Denes Z., et al. Efficacy and safety of treatment with incobotulinum toxin A (botulinum neurotoxin type A free from complexing proteins; NT 201) in post-stroke upper limb spasticity. J Rehabil Med. 2011; 43 (6): 486-492. DOI: 10.2340/16501977-0796.
12. Elovic E. P., Munin M. C., Kaňovský P., et al. Randomized, placebo-controlled trial of incobotulinumtoxina for upper-limb post-stroke spasticity. Muscle & Nerve. 2016; 53 (3): 415-421. DOI: 10.1002/mus.24776.
13. Kaňovský P., Elovic E. P., Angelika Hanschmann A., et al. Duration of Treatment Effect Using IncobotulinumtoxinA for Upper-limb Spasticity: A Post-hoc Analysis. Front Neurol. 2021; 11: 615706. DOI: 10.3389/fneur.2020.615706.
14. Wissel J., Bensmail D., Ferreira J. J., et al. Safety and efficacy of incobotulinum toxin A doses up to 800 U in limb spasticity: The TOWER study. Neurology. 2017; 88 (14): 1321-1328. DOI: 10.1212/WNL.0000000000003789.
15. Wissel J., Camões-Barbosa A., Comes G., et al. Pain Reduction in Adults with Limb Spasticity Following Treatment with IncobotulinumtoxinA: A Pooled Analysis. Toxins (Basel). 2021; 13 (12): 887. DOI: 10.3390/toxins13120887.
16. Kostenko E. V., Petrova L. V. Ganzhula P. A., et al. Experience of using Rseomin in the correction of hand spasticity in the early recovery period of stroke. Zhurnal nevrologii i psikhiatrii im. S. S. Korsakova 2012; 112; 2: 29-34. (In Russ.)
17. Kovalenko A. P., Vozniuk I. A., Naumov K. M., et al. Treatment of spasticity in patients with the consequences of traumatic brain injury. Nevrologiya, neiropsikhiatriya, psikhosomatika. Neurology, Neuropsychiatry, Psychosomatics. 2022; 14 (1): 26-31. (In Russ.) https://doi.org/10.14412/2074-2711-2022-1-26-31
18. Peter P. Urban, Thomas Wolf. http://ahajournals.org
19. Khatkova S.E., Orlova O. R., Botsina A. Yu., et al. Basic principles of management of patients with impaired muscle tone after focal brain injury. Consilium Medicum. 2016. 18 (2.1): 25-33. (In Russ.)
20. Hefter H., Rosenthal D., Jansen A., et al. Significantly lower antigenicity of incobotulinumtoxin than abo- or onabotulinumtoxin. Journal of Neurology. 2023. 270 (2): 788-796. DOI: 10.1007/s00415-022-11395-2.
Review
For citations:
Chirkova M.V. The role of botulinum therapy in the complex recovery of patients after stroke. Lechaschi Vrach. 2025;(1):60-64. (In Russ.) https://doi.org/10.51793/OS.2025.28.1.009
Views:
139
JATS XML
Email this article 
